Clinical Trial Update: Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis [Phase 1]

View source ↗

Summary

Phase 1 study demonstrates pharmacokinetic equivalence between CT-P10 and MabThera (rituximab) in patients with rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CT-P10 (rituximab biosimilar)
• MabThera (rituximab)

Snippet

Sponsor: Celltrion | Conditions: Rheumatoid Arthritis | Phase 1 | Status: COMPLETED